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Abstract
Recent evidence suggests that glaucoma and Alzheimer’s disease are neurodegenerative diseases sharing common
pathophysiological and etiological features, although findings are inconclusive. We sought to investigate whether self-reported
glaucoma patients without dementia present poorer cognitive performance, an issue that has been less investigated. We
employed cross-sectional data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) and included participants
X50 years of age without a known diagnosis of dementia and a self-reported glaucoma diagnosis. We excluded those with
previous stroke, other eye conditions, and using drugs that could impair cognition. We evaluated cognition using delayed word
recall, phonemic verbal fluency, and trail making (version B) tests. We used multinomial linear regression models to investigate
associations between self-reported glaucoma with cognition, adjusted by several sociodemographic and clinical variables. Out
of 4,331 participants, 139 reported glaucoma. Fully-adjusted models showed that self-reported glaucoma patients presented
poorer performance in the verbal fluency test (b=–0.39, 95%CI=–0.64 to –0.14, P=0.002), but not in the other cognitive
assessments. Thus, our results support the hypothesis that self-reported glaucoma is associated with poor cognitive
performance; however, longitudinal data are necessary to corroborate our findings.
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Introduction
Glaucoma is one of the leading causes of preventable
blindness worldwide (1). It is an eye disease characterized
by progressive damage to the optic nerve head and retinal
nerve fiber layer (RNFL), and may be associated with
elevated intraocular pressure in most cases, leading to
increasing vision loss and, eventually, blindness (2). Accu-
mulating evidence suggests an association between glau-
coma and Alzheimer’s disease (AD), as both conditions
share similar epidemiology, such as increased prevalence
in older ages (3), impairment of magnocellular visual
processing (4), and pathophysiological features. For
instance, AD-related neuropathological findings, such as
vacuolar degeneration, neuronal apoptosis, neurofibrillary
tangles, and amyloid-B plaques, have been observed in
the retina as well (3,5), while abnormal retinal findings have
been observed in AD patients, such as reduction of retinal
ganglion cells (RGCs) (6), RNFL (7), and macular thickness
(8). Moreover, cohort studies showed that glaucoma patients
have an increased risk for dementia (9), and dementia
patients have an increased prevalence of glaucoma (10).
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However, cognitive performance in middle-aged indi-
viduals with glaucoma (without dementia) has been rela-
tively less investigated, which could provide useful insights
for the missing links on the actual mechanisms contribut-
ing to the association between glaucoma and dementia.
A large study with 1,485 healthy, middle-aged individuals
showed an association between RNFL and better cognitive
performance (11). This finding is relevant since in glaucoma
progression, the RNFL becomes progressively thinner.
Notwithstanding, in one cohort study of 839 participants
X85 years old, no convincing evidence for an association
between mini-mental state examination (MMSE) and
glaucoma was found (12). In addition, a study with 137
participants found that patients with glaucoma presented
lower performance in the Montreal Cognitive Assessment
(MoCA) compared to controls, but only after adjustment for
confounding variables (13). In contrast, a small study with
60 participants showed lower MMSE scores in glaucoma
vs controls (14). These different findings could be explained
by several limitations in study design, including improper
handling of confounding variables (such as age, educa-
tional level, ethnicity, and clinical comorbidities) and inade-
quate selection of outcome variables, as MMSE and MoCA
are primarily cognitive screening questionnaires, being
suboptimal for the assessment of specific cognitive func-
tions. Moreover, most studies were not conducted in
low- and middle-income countries that present distinct
characteristics regarding ethnicity, socioeconomic condi-
tions, and clinical and neuropsychiatric comorbidities.
Considering these issues, we investigated cognitive
performance in patients with self-reported glaucoma using
cross-sectional data from a large Brazilian cohort, the
Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
According to the assumption that glaucoma is a neurode-
generative illness that might not only affect the visual
system (3), we hypothesized that these patients would
present lower cognitive performance in the evaluated
domains of ELSA-Brasil’s cognitive assessment.
Material and Methods
Overview of ELSA-Brasil
ELSA-Brasil is a cohort of civil servants based on six
universities and research institutions in major Brazilian
cities (São Paulo, Rio de Janeiro, Salvador, Porto Alegre,
Belo Horizonte, and Vitoria) (15). The study was approved
by the local ethics committees, and all participants pro-
vided written, informed consent prior to entering into the
study. The first wave (baseline, n=15,105 participants) of
ELSA-Brasil took place from August 2008 to December
2010. Eligible subjects included all active or retired em-
ployees of these institutions, who were between the ages
of 35 and 74 years old, and free of dementia at enrollment.
Exclusion criteria at baseline were current or recent
(o4 months to the first interview) pregnancy, intention to
quit working at the institution soon, severe cognitive or
communication impairments that hindered an interview,
and, if retired, residence outside the metropolitan area of
the corresponding study center.
Data from participants were collected using a struc-
tured questionnaire about sociodemographic conditions
and self-reported health and disease history, and evalua-
tion of prevalent classical cardiovascular risk factors,
clinical variables, laboratory examination via venipunc-
ture, anthropometric measurements, blood pressure, and
use of medications according to the Anatomic Therapeutic
Chemical (ATC) code. Measurements followed standard-
ized protocols and were collected by certified and trained
technicians.
Study population
For the present analysis, we included only participants
who had: 1) data on self-reported diagnosis of glaucoma;
2) complete data of exposure, outcomes, or covariates;
and 3) X50 years old, as the prevalence of glaucoma
and cognitive deficits in younger adults is very low. We
excluded subjects presenting confounding variables such
as self-reported diagnosis of 1) previous stroke, 2) other
self-reported eye conditions, such as cataracts, retinal
diseases such as diabetic retinopathy, age-related macu-
lar degeneration, and 3) using drugs that could interfere
with cognitive function such as neuroleptics, antiparkinso-
nian drugs, anticonvulsants, and benzodiazepines.
Therefore, for the present study, out of 15,105
participants, 4,086 subjects presented missing values for
eye variables and 4,158 were less than 50 years old.
Other reasons for non-inclusion are described in Figure 1.
Therefore, data from 4,331 participants were analyzed.
Assessments
Eye assessments. Self-reported eye diseases (glau-
coma, cataracts, macular degeneration, corneal diseases,
dry eye, age-related macular retinopathy degeneration,
Figure 1. Study flow chart.
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and diabetic retinopathy), history of use of eye drops,
ointments, lubricants, gels, and medications, and of eye
surgeries and interventions were assessed using a stan-
dardized questionnaire. If ‘‘Yes’’ was the answer given to
the initial question about previous glaucoma diagnosis,
participants had to answer complementary questions
regarding ‘‘previous glaucoma surgery’’, ‘‘use of pilocar-
pine eye drops’’, ‘‘use of [other] eye drop medications’’
(such as beta-blockers, prostaglandin analogues, and
others). In addition, participants were asked to classify the
quality of their vision without correction on a 5-point scale
(Excellent, Good, Regular, Bad, and Very Bad).
Assessments of Cognitive Function. Cognitive function
was assessed using the following tests: a) the Consortium
to Establish a Registry for Alzheimer’s Disease Word List
Memory Test (CERAD-WLMT) (16); b) the Phonemic
Verbal Fluency Test (PVFT) (17); and c) the Trail Making
Test version B (TMT) (18). Trained examiners adminis-
tered these tests in a fixed order during a single session,
in a quiet room with good lighting and low levels of noise
or other distractions. We used the Brazilian version of the
CERAD-WLMT (19). This test comprises immediate word
recall, delayed word recall, and word recognition, and
evaluates the memory domain (16). Participants were
asked to read and learn 10 words after three exposures;
the sum of the number of words recalled in each of these
attempts was the score in the immediate word recall. After
a 5-min filled delay, the participants were given 60 s to
recall the words. The delayed word recall score was equal
to the number of recalled words. Finally, 20 words were
presented and the participants had to recognize the 10
words that were presented previously. In the PVFT,
participants were asked to generate as many words as
possible that started with the letter F to evaluate language
and executive ability. The score on this test was the total
number of generated words (20). Finally, the TMT is a test
of executive function, processing speed, and visual-spatial
organization. The participants were instructed to draw
lines connecting letters and numbers in an order that
alternated between increasing numeric values and alpha-
betic order. The test score was the total time taken to
complete the task, in seconds.
Assessment of covariates. Sociodemographic covari-
ates were collected using structured questionnaires
(15) and were categorized in: 1) age; 2) sex; 3) ethnicity
(white vs non-white); and 4) education (having at least a
university degree).
Presence of any depressive disorder was also includ-
ed as a covariate. It was assessed using the validated
Brazilian version of the Clinical Interview Schedule-
Revised (CIS-R) (21), a structured interview for measure-
ment and diagnosis of non-psychotic psychiatric morbidity
in community, applied by trained interviewers, who are as
reliable as psychiatrists in using CIS-R for performing
mental diagnosis. (22) Introductory questions from the
CIS-R about appetite and fluctuations in weight have not
been included in the ELSA-Brasil questionnaire at wave 1.
As a result, the prevalence of depressive episodes may
have been slightly underestimated.
Anthropometric measurements were assessed using
standard techniques (23). Blood pressure was measured
in a seated position, after 5 min of rest, with a validated
oscillometric device (Omron HEM 705CPINT, Japan).
Three measurements were performed with 1-min intervals
and the mean of the last two readings was considered.
Venous blood samples were obtained following an over-
night fast. Enzymatic assays of the centrifuged serum –
colorimetric and hexokinase method (ADVIA 1200,
Siemenss, Germany) – determined total cholesterol and
fasting plasma glucose, respectively. Clinical risk factors
included as covariates were: 1) presence of hypertension
(use of antihypertensive drug, systolic blood pressure
X140 mm Hg or diastolic blood pressure X90 mm Hg); 2)
presence of diabetes mellitus (self-reported, use of oral
hypoglycemic agents or insulin therapy, fasting plasma
glucose X126 mg/dL, 2-h postprandial 75 g glucose test
X200 mg/dL, or glycosylated hemoglobin X6.5%); 3)
ideal cholesterol levels (total cholesterol o200 mg/dL in
the absence of lipid-lowering medication); 4) ideal smok-
ing status (no smoking history or quit smoking 42 years
vs otherwise); 5) ideal physical activity (defined as X75
min/week of vigorous physical activity, or X150 min/week
of moderate physical activity, or a combination of both vs
otherwise), assessed using the International Physical
Activity Questionnaire (24); 6) presence of cardiac
conditions, such as coronary artery disease (previous
self-reported myocardial infarction or myocardial revascu-
larization), and/or self-reported heart failure; 7) body mass
index (measured in kg/m2); 8) excessive alcohol use
(defined as those with an ethanol consumption X210 and
X140 g/week, for men and women, respectively (25)) and
assessed using the Alcohol Use Questionnaire (26); and
9) presence of thyroid dysfunctions, such as subclinical or
clinical hypo- or hyperthyroidism (normal range: TSH from
0.4 to 4 mIU/L and FT4 levels from 0.8 to 1.9 ng/dL; hypo-
thyroidism: TSH 44.0 mIU/L and FT4 o0.8 ng/dL; and
hyperthyroidism: TSHo0.4 mIU/dL and FT441.9 ng/dL).
Statistical analyses
Analyses were performed with Stata 16 (Statacorp,
USA). We describe sociodemographic and clinical data
using frequencies for categorical variables, and mean and
standard deviations (SD) for continuous variables. Statis-
tical significance was set under an alpha threshold of
0.005, considering the multiple comparisons performed in
our analyses. This lower threshold (compared to the
‘‘standard’’ 0.05) has been proposed as a straightforward
method to reduce the rate of false-positive findings (27) and
was already used in previous studies from our group (28).
The raw scores on the cognitive tests were trans-
formed into z-scores by subtracting each participant’s test
score from the mean score of the sample and dividing the
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difference by the SD of the sample. The z-scores of the
TMT were multiplied by (–1) to indicate that positive and
negative values reflect above and below average perfor-
mance. Finally, a global composite cognitive z-score was
calculated by: 1) averaging the z-scores of all tests and 2)
each individual’s average was standardized using the
mean and SD of the global mean scores.
We performed multiple linear regression models with
robust covariance with cognitive tests (after z-score trans-
formation) as the outcome variable and glaucoma as
the exposure variable. All models were adjusted by the
variables ‘‘previous glaucoma surgery’’, ‘‘use of pilocar-
pine eye drops’’, ‘‘use of [other] eye drop medications’’
(such as beta-blockers, prostaglandin analogues, and
others), and ‘‘quality of vision’’ (dichotomized in (very) bad
vs others, i.e., Average, Good and Very Good). Model 1
was adjusted for the sociodemographic variables age, sex,
race, and education. Model 2 included the variables in
Model 1 plus depression and the 9 clinical variables
mentioned above. In Model 2, if significant main effects for
glaucoma were observed, additional models were per-
formed for variables that presented significant main
effects to test whether there was an interaction between
glaucoma and the covariate.
Results
Overview
Of 4331 participants, 139 (3.2%) reported glaucoma.
These patients presented significantly lower rates of
university degree, non-white ethnicity, and higher rates
of systemic arterial hypertension. Eleven (7.9%) and 13
(9.3%) self-reported glaucoma patients reported they
had undergone glaucoma eye surgery and were using
pilocarpine eye drops, respectively (Table 1).
Association between cognitive performance and
glaucoma
We found a significant association between presence
of glaucoma and lower performance in the phonemic
verbal fluency test for both models, but not for the delayed
word recall and the trail making tests. For the global
composite score, there was a non-significant trend sug-
gesting that patients with glaucoma presented lower
performance (Table 2, Figure 2).
As a significant association for verbal fluency was found,
we tested interactions between glaucoma and covariates
that presented main effects, which were age (Po0.001),
university degree (Po0.001), white ethnicity (Po0.001),
Table 1. Clinical and demographic characteristics of the sample (n=4,331) according to the presence of glaucoma (wave 1 - baseline - of
ELSA-Brasil, 2008–2010).
Variable No Glaucoma (n=4192) Glaucoma (n=139) P value
Female, n (%) 2264 (54.0%) 85 (61.2%) 0.096
Age, mean (SD) 57.5 (5.9) 58.5 (6.0) 0.051
University degree, n (%) 2429 (57.9%) 60 (43.2%) o0.001
White ethnicity, n (%) 2988 (71.4%) 111 (79.9%) o0.001
Good/excellent visual quality, n (%) 1198 (28.6%) 28 (20.1%) 0.029
Any depressive episode, n (%) 132 (3.1%) 6 (4.3%) 0.44
Ideal Physical Activity, n (%) 1073 (26.0%) 31 (22.8%) 0.40
Never smoker, n (%) 3479 (84.3%) 117 (86.0%) 0.59
Heavy drinker, n (%) 350 (8.4%) 13 (9.4%) 0.68
Body mass index (kg/m2), mean (SD) 27.3 (4.7) 27.3 (4.7) 0.95
Ideal cholesterol levels, n (%) 947 (23.0%) 36 (26.5%) 0.34
Diabetes, n (%) 954 (22.8%) 37 (26.6%) 0.29
Systemic arterial hypertension, n (%) 1758 (41.9%) 78 (56.1%) o0.001
Thyroid disorders, n (%)
Hypothyroidism 668 (15.9%) 22 (15.8%) 0.44
Hyperthyroidism 99 (2.4%) 1 (0.7%) 0.44
Self-reported heart failure, n (%) 77 (1.8%) 3 (2.2%) 0.78
Z-scores of cognitive tests
Verbal fluency test, mean (SD) –0.09 (1.01) –0.33 (0.98) 0.004
Delayed word recall test, mean (SD) –0.11 (1.03) –0.19 (1.04) 0.36
Trail making test, mean (SD) –0.16 (1.13) –0.49 (1.45) 0.001
Global composite cognitive score, mean (SD) –0.14 (1.04) –0.38 (1.02) 0.008
For definitions of "ideal" status and estimation of z-scores, please see the main text. Between-group comparisons were performed using
two-sample t-tests and Pearson’s chi-squared tests for continuous and categorical variables, respectively. Bold type indicates significant
differences (Po0.005).
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and diabetes (Po0.001). No significant interaction was
found (all P40.2).
Discussion
The present study investigated the cognitive perfor-
mance of participants with and without self-reported glau-
coma, in a sample of 4331 participants X50 years of age
with no history of stroke, neurocognitive disorders,
cataracts, or retinal diseases, and not using drugs that
interfered at cognitive functioning. We found that glau-
coma patients presented poorer cognitive performance for
the verbal fluency test, an association that remained
significant even after adjustment for several socio-demo-
graphic and cardiovascular risk factors. For the other
cognitive tests evaluated (delayed word recall and trail
Table 2. Association between cognitive performance and glaucoma in the sample (n=4,331) (wave 1 - baseline - of ELSA-Brasil, 2008–
2010).
Model 1 Model 2
Coef (B) 95%CI P Coef (B) 95%CI P
Verbal Fluency test –0.4 –0.65 to –0.14 0.002 –0.395 –0.64 to –0.14 0.002
Delayed word recall test 0.06 –0.19 to 0.3 0.64 0.04 –0.20 to 0.29 0.72
Trail making test –0.21 –0.61 to 0.18 0.28 –0.21 –0.61 to 0.18 0.29
Global composite cognitive score –0.19 –0.40 to 0.03 0.09 –0.19 –0.41 to 0.02 0.08
Results from the multinomial regression models with robust covariance, according to the presence of glaucoma disease. Model 1:
adjusted for age, sex, ethnicity, and education. Model 2: Model 1 + ideal smoking status, ideal physical activity status, hypertension,
diabetes, ideal cholesterol status, presence of cardiac conditions, body mass index, excessive alcohol use, presence of thyroid
dysfunctions, and presence of depression. CI: confidence interval.
Figure 2. Cognitive performance in participants with and without glaucoma. Violin plots of the adjusted predicted values of z-scores of
(A) delayed word recall test, (B) verbal fluency task, (C) trail making test, and (D) global cognitive composite score according to
glaucoma status. Significant results were found only for verbal fluency task (B). Multiple linear regression models with robust covariance
were employed, with adjustment for age, sex, ethnicity, education, ideal smoking status, ideal physical activity status, hypertension,
diabetes, ideal cholesterol status, presence of cardiac conditions, body mass index, excessive alcohol use, presence of thyroid
dysfunctions, and presence of depression.
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making test) and the global cognitive composite score, no
difference in performance was observed between those
with and without glaucoma.
Considering methodological aspects of our present
study, the strengths were: 1) our sample was well charac-
terized through a comprehensive assessment of clinical
risk factors, use of medications, structured interview
about mental disorders, and laboratory assessments; 2)
we could select a specific sample of participants without
major confounding variables, therefore enhancing the
internal validity of our findings; 3) our sample included a
diverse population regarding ethnicity and socioeconomic
levels from different regions in Brazil, enhancing its
generalizability; and 4) we used a stricter alpha threshold
of 0.005, decreasing the chance of false positive findings.
A clear study limitation is the self-reported glaucoma
diagnosis, which can result in misdiagnosis. For instance,
glaucoma suspects could have been treated as glaucoma
(false positives), even with no definitive confirmation in
structural and functional tests. In addition, patients with
asymptomatic glaucoma would be wrongly classified
(false negatives). The net impact of these potential errors
is unknown. Notwithstanding, the overall pattern observed
in our data should still be considered, particularly consid-
ering that, if false negatives are more likely to occur (for
instance, due to greater barriers to healthcare), the true
trends observed in our study would be magnified, and not
decreased, by this limitation.
Other study limitations include: 1) the potential for
residual confounding and reverse causality (due to the
cross-sectional analysis), even after adjustment for sev-
eral covariates; 2) it is possible that the performance of
some cognitive tasks could have been impaired due to
poor vision in both groups and not glaucoma per se.
However, this is unlikely to have occurred for the verbal
fluency test that does not involve visuospatial abilities to
be performed; 3) we did not assess semantic fluency; 4)
we used visual acuity as a covariate adjustment in our
analyses. It should be underscored that such variable is
limited due to its subjective nature, and also because
glaucoma leads to visual complaints only in very ad-
vanced stages, because in most cases defects initially
start in the periphery of the visual fields.
Decreased phonemic verbal fluency performance was
observed in glaucoma patients. This test evaluates lexical
ability and executive functioning, as it requires updating
abilities and inhibitory control for generating new words
according to the provided instructions (20). Accordingly,
the frontal and the temporal cortices are the brain regions
primarily involved in phonemic and semantic verbal flu-
ency performance, respectively (29). In addition, phone-
mic fluency is sensitive to subtle cognitive alterations that
can indicate cognitive declining even in healthier stages
(30). Thus, our findings corroborate the hypothesis that
glaucoma could be a neurodegenerative disease affect-
ing multiple cognitive domains, since glaucoma patients
presented lower performance in this task. Although the
etiological mechanisms were not investigated in this
epidemiological study, one putative mechanism would be
RGCs (a cardinal feature in glaucoma) leading to trans-
synaptic anterograde degeneration in brain areas beyond
the optic nerve (31). In agreement, parameters from
diffusion tensor imaging showed that the fiber number
connectivity in frontal and temporal areas are altered in
glaucoma patients compared to healthy controls (32),
corroborating our findings of poorer verbal fluency in
these patients. Conversely, a recent study did not show
lower verbal fluency in glaucoma patients, a finding that
the authors interpreted as false-negative due to lack of
power (31).
We found no decreased performance in the trail
making and delayed word recall in patients with and
without glaucoma. This is in contrast with a study showing
decreased performance in similar tasks measuring work-
ing memory (digit span) and logic memory in those with
glaucoma (31). However, differences in the tests could
explain the distinct findings, since the trail making test also
involves visuospatial functions in contrast with the digit
span whereas logic memory requires the recall of a
detailed short story and not only a list of words, being
more robust to biases related to learning through repeated
exposure. A recent study with 31 older adults with mild to
moderate glaucoma and age-matched controls explored
the performance of a computerized trail making test with
different levels of complexity based on target contrast and
position, observing that glaucoma patients performed
poorer in these tasks, an impairment that was associated
with the useful field-of-view (33). Possibly, poorer trail
making performance would have been observed in our
glaucoma sample if more specific tests had been employed.
In summary, we found decreased verbal fluency
performance in middle-aged and older patients with glau-
coma and no neurocognitive disorders. Our study is
important as it suggests possible etiological links to obser-
vations that glaucoma is a neurodegenerative disease.
Further longitudinal studies are necessary to better under-
stand whether these cognitive findings precede the devel-
opment of dementia, as well as to investigate whether
early cognitive interventions in glaucoma patients can
prevent or reverse the development of cognitive deficits.
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